The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Anti-spasticity agents for multiple sclerosis
Open accessAbstract
BACKGROUND: Spasticity is a common problem in MS patients causing pain, spasms, loss of function and difficulties in nursing care. A variety of oral and parenteral medications are available. OBJECTIVES: To assess the absolute and comparative efficacy and tolerability of anti-spasticity agents in multiple sclerosis (MS) patients. SEARCH STRATEGY: Randomised controlled trials (RCTs) of anti-spasticity agents were identified using MEDLINE, EMBASE, bibliographies of relevant articles, personal communication, manual searches of relevant journals and information from drug companies. SELECTION CRITERIA: Double-blind, randomised controlled trials (either placebo-controlled or comparative studies) of at least seven days duration. DATA COLLECTION AND ANALYSIS: Two independent reviewers extracted data and the findings of the trials were summarised. Missing data were collected by correspondence with principal investigators. A meta-analysis was not performed due to the inadequacy of outcome measures and methodological problems with the studies reviewed. MAIN RESULTS: Twenty-three placebo-controlled studies (using baclofen, dantrolene, tizanidine, botulinum toxin, vigabatrin, prazepam and threonine) and thirteen comparative studies met the selection criteria. Only thirteen of these studies used the Ashworth scale, of which only three of the six placebo-controlled trials and none of the seven comparative studies showed a statistically significant difference between test drugs. Spasms, other symptoms and overall impressions were only assessed using unvalidated scores and results of functional assessments were inconclusive. REVIEWER'S CONCLUSIONS: The absolute and comparative efficacy and tolerability of anti-spasticity agents in multiple sclerosis is poorly documented and no recommendations can be made to guide prescribing. The rationale for treating features of the upper motor neurone syndrome must be better understood and sensitive, validated spasticity measures need to be developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.
Ashworth, B. (1964) · PubMed · Cited by 1,475
Merkies, I. S. J., & Kieseier, B. C. (2016) · European Neurology · doi:10.1159/000445347 · Cited by 869
Pandyan, A. D., Johnson, G. R., Price, C. I. M., Curless, R. H., Barnes, M. P., & Rodgers, H. (1999) · Clinical Rehabilitation · doi:10.1191/026921599677595404 · Cited by 833
Intrathecal Baclofen for Severe Spinal Spasticity
Penn, R. D., Savoy, S. M., Corcos, D., Latash, M., Gottlieb, G., Parke, B., & Kroin, J. S. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906083202303 · Cited by 754
Measurement In Neurological Rehabilitation
Harms, M. (1992) · Physiotherapy · doi:10.1016/s0031-9406(10)60484-1 · Cited by 530
Wade, D. T., Robson, P., House, H., Makela, P., & Aram, J. (2003) · Clinical Rehabilitation · doi:10.1191/0269215503cr581oa · Cited by 441
Treatment of spasticity with botulinum toxin: A double‐blind study
Snow, B. J., Tsui, J. K. C., Bhatt, M. H., Varelas, M., Hashimoto, S. A., & Calne, D. B. (1990) · Annals of Neurology · doi:10.1002/ana.410280407 · Cited by 414
Measurement in neurological rehabilitation.
Wade, D. T. (1992) · PubMed · Cited by 351
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis
Collin, C., Davies, P., Mutiboko, I. K., Ratcliffe, S., & for the Sativex Spasticity in MS Study Group (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01639.x · Cited by 379
Givon, U., Zeilig, G., & Achiron, A. (2009) · Gait & Posture · doi:10.1016/j.gaitpost.2008.07.011 · Cited by 314
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed
Feinstein, A., Freeman, J., & Lo, A. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70231-5 · Cited by 281
Metadata
- Authors
- Shakespeare, D., Boggild, M., & Young, C. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2003-10-20
- Volume
- 2010
- Issue
- 1
- Pages
- CD001332-CD001332
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2158699108
- Cited by
- 271
- References
- 68
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-spasticity agents for multiple sclerosis. https://app.cochat.ai/papers/10.1002/14651858.cd001332
- The paper
- Shakespeare, D., Boggild, M., & Young, C. A. (2003). Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001332
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.